Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study

Abstract

The optimal therapeutic management of patients with antiphospholipid syndrome (APS) during pregnancy is debatable. In the present prospective cohort study the use of a low molecular weight heparin (LMWH) (nadroparin), administered alone twice daily in 30 pregnant women who were diagnosed with APS on the basis of the current classification criteria, is evaluated. Dosage was adjusted according to anti-Xa levels in the patients as the pregnancies progressed. Three women, in whom an important gradual fall in platelet count in the first trimester did not respond to increased nadroparin doses, were shifted to a second-line treatment protocol. Fetal loss occurred in two of the 27 remaining women (7.40%), while 25 (92.59%) delivered 25 live infants, between the 32nd and 40th weeks of gestation. No fetal problems were registered during pregnancies, while maternal complications occurred in two of the 25 patients (8%). Moreover, there were no thrombotic events in any of the women during the study. Patient compliance was good and only minor side-effects were reported. The results of this study indicate that nadroparin alone is useful and safe in the management of pregnant patients with APS. However, in consideration of the good pregnancy outcome obtained in patients with only pregnancy morbidity when heparin and aspirin were used together, other studies comparing nadroparin twice daily with once daily plus Aspirin would be useful to ascertain which is more effective in these patients.

Keywords

antiphospholipid antibodies antiphospholipid syndrome low molecular weight heparin nadroparin pregnancy

Get full access to this article

View all access options for this article.

References

Tincani A , Branch W , Levy RA et al. Treatment of pregnant patients with antiphospholipid syndrome . Lupus 2003; 12: 524-529 .

Empson M , Lassere M , Craig JC , Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials . Obstet Gynecol 2002; 99: 135-144 .

Branch DW , Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management and controversies . Obstet Gynecol 2003; 101: 1333-1344 .

Lima F , Khamashta MA , Buchanan NMM , Kerslake S , Hunt BJ , Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome . Clin Exp Rheumatol 1996; 14: 131-136 .

Stone S , Hunt BJ , Seed PT , Parmar K , Khamashta MA , Poston L. Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and healthy pregnancy . Am J Obstet Gynecol 2003; 188: 454-460 .

Ensom MH , Stephenson MD. Low-molecular-weight heparins in pregnancy . Pharmacotherapy 1999; 19: 1013-1025 .

Sanson BJ , Lensing AWA , Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review . Thromb Haemost 1999; 81: 668-672 .

Makatsaria AD , Bitsadze VO , Dolgushina NV. Use of the low-molecular-weight heparin nadroparin during pregnancy. A review . Curr Med Res Opin 2003; 19: 4-12 .

Di Simone N , Caliandro D , Castellani R , Ferrazzani S , De Carolis S , Caruso A. Low-molecular-weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome . Hum Reprod 1999; 14: 489-495 .

10.

Ermel LD , Marshburn PB , Kutteh WH. Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL) . Am J Reprod Immunol 1995; 33: 14-20 .

11.

Franklin RD , Kutteh WH. Effects of unfractionated and low-molecular-weight heparin on antiphospholipid antibody binding in vitro . Obstet Gynecol 2003; 101: 455-462 .

12.

Wilson WA , Gharavi AE , Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome . Arthritis Rheum 1999; 42: 1309-1311 .

13.

Chigot P , DE Gennes C , Samama MM. Effects of unfragmented and low weight heparin and the induction of osteoporosis . J Mal Vasc 1996; 21: 121-125 .

14.

Tincani A , Balestrieri G , Allegri F et al. Overview on anticardiolipin ELISA standardization . J Autoimmun 2000; 15: 195-197 .

15.

Brandt JT , Triplett DA , Alving B , Scarrer I. Criteria for the diagnosis of lupus anticoagulants: an update . Thromb Haemostasis 1995; 74: 1185-1190 .

16.

Galton M , Merritt K , Beller FK. Coagulation studies on the peripheral circulation of patients with toxaemia of pregnancy: a study for the evaluation of disseminated extravascular coagulation and toxaemia . J Reprod Med 1971; 6: 89-100 .

17.

Redman CWG , Bonnar J , Beilin L. Early platelet consumption in pre-eclampsia . Br Med J 1978; 1: 467-469 .

18.

Lindheimer MD , Katz AI. Pathophysiology of pre-eclampsia . Ann Rev Med 1981; 32: 273-289 .

19.

Romero R , Mazor M , Lockwood CJ. Clinical significance, prevalence and natural history of thrombocytopenia in pregnancy-induced hypertension . Am J Perinatol 1989; 6: 32-38 .

20.

Shiach CR. Monitoring of low molecular weight heparin in pregnancy . Hematol 2003; 8: 47-52 .

21.

Sephton V , Farquharson RG , Topping J et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy . Obstet Gynecol 2003; 101: 1307-1311 .

22.

Nelson-Piercy C , Letsky EA , de Swiet M. Low-molecular weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk . Am J Obstet Gynecol 1997; 176: 1062-1068 .

23.

Blombäck M , Bremme K , Hellgren M , Siegbahn A , Lindbeg H. Thromboprophylaxis with low molecular mass heparin, ‘Fragmin’ (dalteparin), during pregnancy—a longitudinal safety study . Blood Coagul Fibrinolysis 1998; 9: 1-9 .

24.

Melissari E , Parker C , Wilson NV et al. Use of low molecular weight heparin in pregnancy . Thromb Haemost 1992; 68: 652-656 .

25.

Boda Z , Laszlo P , Rejtõ et al. Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy . Thromb Haemost 1996; 76: 128-128 .

26.

Hunt BJ , Doudhty HA , Majumdar G et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies . Thromb Haemost 1997; 77: 39-43 .

27.

Casele HL , Laiefer SA , Woelkers DA , Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy . Am J Obstet Gynecol 1999; 181: 1113-1117 .

28.

Pettila V , Kaaja R , Leinonen P , Ekblad P , Kataja M , Ikkala E. Thromboprophylaxis with low molecular weight heparin (Dalteparin) in pregnancy . Thromb Res 1999; 96: 275-282 .

29.

Bonnar J , Green R , Norris L. Perinatal aspects of inherited thrombophilia . Semin Thromb Haemost 1999; 25: 481-485 .

30.

Ginsberg JS , Greer I , Hirsh J. Use of antithrombotic agents during pregnancy . Chest 2001; 119: 122S-131S .

31.

Fiehn C. Treatment of woman with aPL in pregnancy . Ann Rheum Dis 2001; 60: 717-718 (letter).

32.

Ruffatti A , Chiarelli S , Favaro M et al. Could placental abruption be an antiphospholipid related disorder ? Clin Exp Rheumatol 2004; 22: 380-381 (letter).

33.

Asherson RA , Piette JC , Cervera R. ‘Primary’, ‘Secondary’, ‘Seronegative’, ‘Catastrophic’ and other subsets of the Antiphospholipid Syndrome. In Asherson RA , Cervera R , Piette JC , Shoenfeld Y ed. The Antiphospholipid Syndrome II. Elsevier Science: Amsterdam , 2002: 285-296.

34.

Ruffatti A , De Silvestro G , Ghirardello A et al. A catastrophic antiphospholipid syndrome: the importance of high levels of warfarin anticoagulation . J Intern Med 1994; 235: 81-83 .

35.

Watson WJ , Katz VL , Bowes WA Jr. Plasmapheresis during pregnancy . Obstet Gynecol 1990; 76: 451-457 .

36.

Rock JA , Shirey RS , Braine HG , Ness PM , Kickler TS , Niebyl JR. Plasmapheresis for the treatment of repeated early pregnancy wastage associated with anti-P . Obstet Gynecol 1985; 66: 57S-60S .

37.

Huong TLD , Wechsler B , Bletry O , Vauthier-Brouzes D , Lefebvre G , Piette J-C. A study of 75 pregnancies in patients with antiphospholipid syndrome . J Rheumatol 2001; 28: 2025-2030 .

38.

Rosove MH , Tabsh K , Wasserstrum N , Howard P , Hahn BH , Kalunian K. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antobodies . Obstet Gynecol 1990; 75: 630-634 .

39.

Ruffatti A , Orsini A , Di Lenardo L et al. A prospective study of fifty-three consecutive calcium heparin treated pregnancies in patients with antiphospholipid antibody-related fetal loss . Clin Exp Rheumatol 1997; 15: 499-505 .

40.

Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone . Am J Obstet Gynecol 1996; 174: 1584-1589 .

41.

Rai R , Cohen H , Dave M , Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) . BMJ 1997; 314: 253-257 .